These are the 'new' / 'interesting' bits of info I got out of this presentation
- Production capacity for TEMCELL is currently being increased as JCR has received orders far in excess of initial forecasts - this is a different narrative to the manufacturing issues mentioned in BP report, will be interesting to see if there's any further mention on this.
- COVID 19 ARDS trial expected to complete recruitment in Q4FY20 - here's hoping for the positive early readout!
- Post marketing study for aGVhD - planning underway: 'post-marketing' hopefully means they know an FDA approval is coming for paediatric!
- First patient has been treated for MIS-C and has been discharged from the hospital - implies a positive outcome!
- Label extensions for RYONCIL include Bacterial ARDS and Influenza ARDS - large addressable markets
- CHF & CLBP readouts 'expected' Q4FY20 - delays on these are a little frustrating but looks like RYONCIL is the priority
Ann: Annual Financial Results Presentation, page-4
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.25 |
Change
0.035(2.89%) |
Mkt cap ! $1.421B | |||
| Open | High | Low | Value | Volume |
| $1.21 | $1.25 | $1.18 | $4.096M | 3.347M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22000 | $1.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 36989 | 4 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |